In our study, DNA methylation inhibitors were used in three of seven patients in the no‐dysplasia group and four of six in the dysplasia group; the survival times of these groups were 43–62 months and 8–25 months, respectively (P = .018), which may suggest that der(1;7) MDS patients with no dysplasia possess the TP53 mutation, which leads to a survival benefit. Here, TP53 is linked to myelodysplastic syndrome.